John Crowley, chairman and former CEO of Amicus Therapeutics, joins the show to discuss the strides the biotech industry has made in therapies for rare genetic diseases and the industry landscape going forward. (This interview originally aired as part of Wharton Business Daily’s Business of Healthcare special.)
Listen to the podcast.
